2024-07-122024-07-122020Özünal, Z. G., Dönmez Çakıl, Y., Sağlam, E. ve Aktaş, R. G. (2020). Effect of escitalopram alone or combination wıth sorafenib on hepg2 hepatocellular cell line proliferation. Research and Science Today, RST Journal. 1(19), s. 201-210.2247-44552285-9632https://www.rstjournal.com/mdocs-posts/20-zeynep-gunes-ozunal-yaprak-donmez-cakil-esra-saglam-et-all-effect-of-escitalopram-alone-or-combination-with-sorafenib-on-hepg2-hepatocellular-cell-line-proliferation/https://hdl.handle.net/20.500.12415/4318Hepatocellular carcinoma is one of the most common cancers. The main treatment for hepatocellular cancers is surgery. Drug treatment can be performed in advanced cases after surgical treatment or relapse therapy. Sorafenib is a drug that is used primarily in the treatment of hepatocellular cancer. Escitalopram is a drug in the serotonin reuptake inhibitor group used to treat depression. There are studies showing the effect of escitalopram on proliferation. The purpose of this study is to evaluate the use of escitalopram alone and in combination with sorafenib in liver cancer. The effect of escitalopram and in combination on proliferation of hepatocellular cell lines was assessed by xtt proliferation assay. The half inhibiting concentration (ic 50) was calculated by regression analysis, photographed under an inverted microscope. The synergistic effect has been evaluated. The effect on morphological changes was visualized under the inverted microscope. The results of our study confirm the synergistic effect of use of escitalopram in combination with sorafenib in liver cancer. Prospective randomized trials are needed to evaluate its clinical use.frAttribution-NonCommercial-NoDerivs 3.0 United Statesinfo:eu-repo/semantics/openAccessEscitalopramhepg2proliferationsorafenibcancerArticle210192011